Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, her2-positive early breast cancer: Results from the BCIRG 006 study
Background. This study aims to describe and compare health- related quality of life (HRQL) in patients with node-positive and high-risk node-negative HER2-positive early breast can-cer receiving adjuvant docetaxel and trastuzumab-based or docetaxel-based regimens alone. Methods. Eligible patients (n...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal Article |
| Published: |
AlphaMed Press
2013
|
| Online Access: | http://hdl.handle.net/20.500.11937/12232 |
| _version_ | 1848748020595687424 |
|---|---|
| author | Au, H. Eiermann, W. Robert, N. Pienkowski, T. Crown, J. Martin, M. Pawlicki, M. Chan, Arlene Mackey, J. Glaspy, J. Pintér, T. Liu, M. Fornander, T. Sehdev, S. Ferrero, J. Bée, V. Santana, M. Miller, D. Lalla, D. Slamon, D. |
| author_facet | Au, H. Eiermann, W. Robert, N. Pienkowski, T. Crown, J. Martin, M. Pawlicki, M. Chan, Arlene Mackey, J. Glaspy, J. Pintér, T. Liu, M. Fornander, T. Sehdev, S. Ferrero, J. Bée, V. Santana, M. Miller, D. Lalla, D. Slamon, D. |
| author_sort | Au, H. |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | Background. This study aims to describe and compare health- related quality of life (HRQL) in patients with node-positive and high-risk node-negative HER2-positive early breast can-cer receiving adjuvant docetaxel and trastuzumab-based or docetaxel-based regimens alone. Methods. Eligible patients (n = 3,222) were randomly assigned to either four cycles of adjuvant doxorubicin and cyclophosphamide followed by four cycles of docetaxel (AC-T) or one of two trastu- zumab-containing regimens: adjuvant doxorubicin and cyclophos- phamidefollowed bydocetaxel plustrastuzumabadministeredfor1 year (AC-TH) or six cycles of docetaxel pluscarboplatin combined with trastuzumab administered for 1 year (TCH). The European Or-ganization for Research andTreatment of Cancer (EORTC)Qualityof Life Questionnaire C30 and BR-23 were administered at baseline, thestartofcycle4(mid),andtheendofchemotherapy(EOC),aswell as at 6,12, and 24 months after chemotherapy. Results. Compliance rates for the EORTC questionnaires were acceptable at 72%-93% of eligible patients out to the 12- month assessment. Systemic side effect (SE) change scores were significantly improved for TCH-treated patients com-pared with AC->TH and AC-T at EOC, suggesting improved tolerability. Physical functioning (PF) was only slightly worse at midpoint for those receiving TCH, compared with patients who were just starting on taxane in an AC-TH regimen, but was otherwise similar between arms. All treatment arms re-covered from the deterioration in SE, PF, and Global Health Scale scores by 1 year and median future perspective change scores continued to improve throughout treatment and fol-low-up. Conclusion. HRQL outcomes for adjuvant docetaxel and trastu- zumab-based regimens are favorable and support TCH as a more tolerable treatment option. © AlphaMed Press 2013. |
| first_indexed | 2025-11-14T06:58:24Z |
| format | Journal Article |
| id | curtin-20.500.11937-12232 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T06:58:24Z |
| publishDate | 2013 |
| publisher | AlphaMed Press |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-122322023-02-22T06:24:22Z Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, her2-positive early breast cancer: Results from the BCIRG 006 study Au, H. Eiermann, W. Robert, N. Pienkowski, T. Crown, J. Martin, M. Pawlicki, M. Chan, Arlene Mackey, J. Glaspy, J. Pintér, T. Liu, M. Fornander, T. Sehdev, S. Ferrero, J. Bée, V. Santana, M. Miller, D. Lalla, D. Slamon, D. Background. This study aims to describe and compare health- related quality of life (HRQL) in patients with node-positive and high-risk node-negative HER2-positive early breast can-cer receiving adjuvant docetaxel and trastuzumab-based or docetaxel-based regimens alone. Methods. Eligible patients (n = 3,222) were randomly assigned to either four cycles of adjuvant doxorubicin and cyclophosphamide followed by four cycles of docetaxel (AC-T) or one of two trastu- zumab-containing regimens: adjuvant doxorubicin and cyclophos- phamidefollowed bydocetaxel plustrastuzumabadministeredfor1 year (AC-TH) or six cycles of docetaxel pluscarboplatin combined with trastuzumab administered for 1 year (TCH). The European Or-ganization for Research andTreatment of Cancer (EORTC)Qualityof Life Questionnaire C30 and BR-23 were administered at baseline, thestartofcycle4(mid),andtheendofchemotherapy(EOC),aswell as at 6,12, and 24 months after chemotherapy. Results. Compliance rates for the EORTC questionnaires were acceptable at 72%-93% of eligible patients out to the 12- month assessment. Systemic side effect (SE) change scores were significantly improved for TCH-treated patients com-pared with AC->TH and AC-T at EOC, suggesting improved tolerability. Physical functioning (PF) was only slightly worse at midpoint for those receiving TCH, compared with patients who were just starting on taxane in an AC-TH regimen, but was otherwise similar between arms. All treatment arms re-covered from the deterioration in SE, PF, and Global Health Scale scores by 1 year and median future perspective change scores continued to improve throughout treatment and fol-low-up. Conclusion. HRQL outcomes for adjuvant docetaxel and trastu- zumab-based regimens are favorable and support TCH as a more tolerable treatment option. © AlphaMed Press 2013. 2013 Journal Article http://hdl.handle.net/20.500.11937/12232 10.1634/theoncologist.2013-0091 AlphaMed Press unknown |
| spellingShingle | Au, H. Eiermann, W. Robert, N. Pienkowski, T. Crown, J. Martin, M. Pawlicki, M. Chan, Arlene Mackey, J. Glaspy, J. Pintér, T. Liu, M. Fornander, T. Sehdev, S. Ferrero, J. Bée, V. Santana, M. Miller, D. Lalla, D. Slamon, D. Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, her2-positive early breast cancer: Results from the BCIRG 006 study |
| title | Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, her2-positive early breast cancer: Results from the BCIRG 006 study |
| title_full | Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, her2-positive early breast cancer: Results from the BCIRG 006 study |
| title_fullStr | Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, her2-positive early breast cancer: Results from the BCIRG 006 study |
| title_full_unstemmed | Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, her2-positive early breast cancer: Results from the BCIRG 006 study |
| title_short | Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, her2-positive early breast cancer: Results from the BCIRG 006 study |
| title_sort | health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, her2-positive early breast cancer: results from the bcirg 006 study |
| url | http://hdl.handle.net/20.500.11937/12232 |